De VrieseA.S.D., MortierS., LameireN.H.. What happens to the peritoneal membrane in long-term peritoneal dialysis.Perit Dial Int2001; 21(Suppl 3): S9–18.
2.
VardhanA., ZweersM.M., GokalR., KreidetR.T.. A solutions portfolio approach in peritoneal dialysis.Kidney Int2003; 64(Suppl 88): S114–23.
3.
WitowskiJ., WisniewskaJ., KorybalskaK.Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells.J Am Soc Nephrol2001; 12: 2434–41.
4.
WolfsonM., OgrincF., MujaisS.. Review of clinical trial experience with icodextrin.Kidney Int2002; 62(Suppl 81): S46–52.
5.
YoungG.A., KoppleJ.D., LindholmB.Nutritional assessment of continuous ambulatory peritoneal dialysis. An international study.Am J Kidney Dis1991; 17: 462–71.
6.
LopezE.G., LindholmB., TranaeusA.. Biocompatibility of new peritoneal dialysis solutions: Clinical experience.Perit Dial Int2000; 20(Suppl 5): S48–56.
MortierS., FaictD., SchalkwijkC.G., LameireN.H., VrieseA.S.D.. Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane.Kidney Int2004, 66: 1257–65.
9.
WilliamsJ.D., TopleyN., CraigK.J.The Euro-Balance trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on peritoneal membrane.Kidney Int2004; 66: 408–18.
